Evaluation of immune-related response criteria (irRC) in patients (pis) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475

F. Stephen Hodi, Antoni Ribes, Adil Daud, Omid Hamid, Caroline Robert, Richard Kefford, Wan-Jan Hwu, Tara C. Gangadhar, Anthony M. Joshua, Peter Hersey, Jeffrey S. Weber, Roxana Stefanie Dronca, Andrea Marie Perrone, Linda Gammage, Darcy Mille, Dahai Xue, Soonmo Peter Kang, Patrick Chun, Scot Ebbinghaus, Jedd D. Wolchok

Research output: Contribution to journalMeeting abstract

Abstract

Background: Unique response patterns have been observed with immunotherapies, and both objective response and prolonged disease stabilization can occur after an initial increase in tumor size. irRC were developed to better characterize response to immunotherapy, but it is unclear how irRC perform in pts treated with PD-1 blockade. Here, we describe unique patterns of response to MK-3475 in MEL pts and evaluate irRC as an alternative criterion for comprehensive response assessment.

Methods: Source population was pts from 3 MEL cohorts treated with MK-3475 2 mg/kg every 3 wk (Q3W), 10 mg/kg Q3W, or 10 mg/kg Q2W in a phase I trial. Tumor imaging was performed every 12 wk. Response was assessed by irRC and RECIST 1.1 by central review; irRC was used for pt management. Tumor flare and atypical delayed response were identified by using centrally assessed irRC data among pts on MK-3475 for ≥28 wk. Tumor flare was defined as unconfirmed PD at assessment 1 (ie, wk 12) and non-PD at assessment 2. Atypical delayed response was defined as PD at any time point followed by non-PD and then response. Survival data were analyzed in pts who had PD by RECIST but CR/PR/SD by irRC.

Results: Among the 411 pts enrolled across the 3 MEL cohorts, 192 were on MK-3475 for ≥28 wk as of the analysis cut-off of 10/18/2013. Tumor flare was seen in 7 (3.6%) pts. In these pts, best overall response per irRC was CR (n = 1), PR (n = 4), and SD (n = 2). Atypical delayed response was seen in 6 (3.1%) pts. The 51 pts with PD by RECIST but CR/PR/SD by irRC had favorable OS compared with the 145 pts with PD by both criteria (Table).

Conclusions: MEL pts treated with MK-3475 may experience unique patterns of response and should be managed accordingly. Similar to what has been observed with ipilimumab, conventional criteria such as RECIST may underestimate the benefit of MK-3475 in approximately 10% of treated pts. An updated version of response criteria that incorporate new data on PD-1 inhibitors may be appropriate for future consideration. Clinical trial information: NCT01295827.
Original languageEnglish
Pages (from-to)LBA9000-LBA9000
Number of pages1
JournalJournal of Clinical Oncology
Volume32
Issue number15 Supplementary
DOIs
Publication statusPublished - 20 May 2014
Externally publishedYes
Event50th Annual Meeting of the American-Society-of-Clinical-Oncology - Chicago, United States
Duration: 30 May 20143 Jun 2014

Cite this